Eradication Confirmation

H.pylori test kits (Antigen) are Class II medical devices (FDA-cleared/CE-marked) for rapid immunochromatographic or enzyme immunoassay detection of Helicobacter pylori antigens in stool specimens, enabling non-invasive diagnosis of active infection and post-treatment eradication confirmation. Test principles use monoclonal or polyclonal antibodies specific to H. pylori antigens, producing visible results in 10-20 minutes (rapid tests) or 1-2 hours (EIA). Sensitivity 90-98%, specificity 92-99% compared to gold standard methods. Primary clinical applications include rapid diagnosis of H. pylori infection in patients with dyspepsia, initial screening in uncomplicated dyspepsia (test-and-treat strategy), confirmation of active infection before therapy, post-treatment eradication confirmation (4-6 weeks after therapy), pediatric testing (preferred non-invasive method), screening in high-risk populations (family history of gastric cancer), and monitoring in patients with peptic ulcer disease or MALT lymphoma. Critical safety precautions include mandatory washout period (4 weeks off antibiotics, 2 weeks off PPIs) to avoid false negatives, proper specimen handling (universal precautions), refrigerated storage of kits (2-30°C), quality control verification, and disposal as biohazardous waste. Essential non-invasive tool for H. pylori management in gastroenterology and primary care.